Blair William & Co. IL Lowers Stake in TransMedics Group, Inc. $TMDX

Blair William & Co. IL lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 16.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,443 shares of the company’s stock after selling 11,044 shares during the quarter. Blair William & Co. IL owned approximately 0.17% of TransMedics Group worth $6,445,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in TransMedics Group in the third quarter valued at about $28,000. Optiver Holding B.V. grew its stake in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares during the last quarter. LOM Asset Management Ltd bought a new position in TransMedics Group in the third quarter worth about $34,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of TransMedics Group during the second quarter valued at about $48,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on TMDX. Oppenheimer boosted their price objective on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Morgan Stanley raised their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Piper Sandler upped their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $152.33.

Insider Buying and Selling at TransMedics Group

In related news, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This represents a 6.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 3,571 shares of TransMedics Group stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total value of $524,294.22. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,781,513.88. This represents a 22.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,205 shares of company stock worth $2,353,002 in the last three months. 7.00% of the stock is owned by company insiders.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $130.85 on Wednesday. The firm has a market capitalization of $4.49 billion, a P/E ratio of 26.70 and a beta of 1.98. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average price of $135.76 and a 200 day moving average price of $127.15. TransMedics Group, Inc. has a 52 week low of $62.23 and a 52 week high of $156.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.